Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication)

,

doi:10.5217/ir.2018.16.2.178

Cited by 20 publications

(14 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effective suppression of the protozoa by the antibiotic gavage and L-fucose supplementation promoted recovery in the mice. Current approaches being used for IBD treatment often do not consider the variety of the microorganisms inhabiting the gastrointestinal tract [ 85 , 86 ], including protozoa. Our results imply that this may result in health deterioration in individuals defective in gut barrier due to overgrowth of non-bacterial agents.…”

Section: Discussionmentioning

confidence: 99%

Fucose Ameliorates Tritrichomonas sp.-Associated Illness in Antibiotic-Treated Muc2−/− Mice

Achasova

Kozhevnikova

Borisova

et al. 2021

IJMS

View full text Add to dashboard Cite

The mucus layer in the intestine plays a critical role in regulation of host–microbe interactions and maintaining homeostasis. Disruptions of the mucus layer due to genetic, environmental, or immune factors may lead to inflammatory bowel diseases (IBD). IBD frequently are accompanied with infections, and therefore are treated with antibiotics. Hence, it is important to evaluate risks of antibiotic treatment in individuals with vulnerable gut barrier and chronic inflammation. Mice with a knockout of the Muc2 gene, encoding the main glycoprotein component of the mucus, demonstrate a close contact of the microbes with the gut epithelium which leads to chronic inflammation resembling IBD. Here we demonstrate that the Muc2−/− mice harboring a gut protozoan infection Tritrichomonas sp. are susceptible to an antibiotic-induced depletion of the bacterial microbiota. Suppression of the protozoan infection with efficient metronidazole dosage or L-fucose administration resulted in amelioration of an illness observed in antibiotic-treated Muc2−/− mice. Fucose is a monosaccharide presented abundantly in gut glycoproteins, including Mucin2, and is known to be involved in host–microbe interactions, in particular in microbe adhesion. We suppose that further investigation of the role of fucose in protozoan adhesion to host cells may be of great value.

show abstract

Section: Discussionmentioning

confidence: 99%

Fucose Ameliorates Tritrichomonas sp.-Associated Illness in Antibiotic-Treated Muc2−/− Mice

Achasova

Kozhevnikova

Borisova

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Although these drugs have been shown to be highly effective in the induction and maintenance of clinical and endoscopic remission, potential AEs can cause significant morbidity and mortality. Anti-TNFs have been associated with a wide range of AEs, including the increased risk of infections (viral, bacterial, fungal, or opportunistic) [ 16 , 17 , 18 ]; hematological disorders (leukopenia, thrombocytopenia, and/or anemia as well as non-Hodgkin’s lymphoma) [ 19 , 20 , 21 , 22 , 23 ]; and dermatological AEs including skin malignancies, psoriasis, granuloma annulare, interstitial granulomatous dermatitis, and erythema nodosum [ 24 , 25 ]. Demyelination has been recognized as a neurological AE of anti-TNFs both in the central and peripheral nervous system [ 26 , 27 ].…”

Section: Discussionmentioning

confidence: 99%

Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study

Veisman

Barzilay

Bruckmayer

et al. 2021

JCM

View full text Add to dashboard Cite

Infliximab and vedolizumab are effective treatments for inflammatory bowel disease (IBD), although associated with adverse events (AE). While low or non-existent drug levels and positive antidrug antibodies have been associated with therapeutic failure, there is no clear association between higher drug levels and AE. A cross-sectional study consisting of Crohn’s disease (CD) and ulcerative colitis (UC) patients receiving infliximab or vedolizumab at the Sheba Medical Center was performed. Patients completed a questionnaire regarding AEs related to biological therapy. Serum trough levels obtained on the same day were analyzed. Objective measures of outcomes were retrieved from medical records. Questionnaires were completed by infliximab (n = 169) and vedolizumab (n = 88)-treated therapy patients. Higher infliximab levels were only numerically associated with the occurrence of at least one AE (p = 0.08). When excluding fatigue and abdominal pain, higher infliximab levels were statistically associated with the occurrence of at least one AE (p = 0.03). Vedolizumab drug levels > 18μg/mL were also linked with the occurrence of more AEs. No specific association was observed between the increased levels of either infliximab or vedolizumab and specific AEs (neurological symptoms, upper GI symptoms, infectious complications, and musculoskeletal symptoms). As significant AEs are very rare, additional multi-center studies are required.

show abstract

“…Inflammatory bowel disease (IBD), which is a general term for Crohn’s disease and ulcerative colitis, is caused by opportunistic infection or immune cell infiltration. 151,152 A meta-analysis published by Radel et al . has indicated that DPP-4 inhibition can increase the risk of Crohn’s disease.…”

Section: Methods For Screening Novel Dpp-4 Inhibitorsmentioning

confidence: 99%

The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from in silico to in vivo

Lin

Tsai

Cheng

et al. 2019

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Dipeptidyl peptidase IV (DPP-4), an incretin glucagon-like peptide-1 (GLP-1) degrading enzyme, contains two forms and it can exert various physiological functions particular in controlling blood glucose through the action of GLP-1. In diabetic use, the DPP-4 inhibitor can block the DDP-4 to attenuate GLP-1 degradation and prolong GLP-1 its action and sensitize insulin activity for the purpose of lowering blood glucose. Nonetheless the adverse effects of DPP-4 inhibitors severely hinder their clinical applications, and notably there is a clinical demand for novel DPP-4 inhibitors from various sources including chemical synthesis, herbs, and plants with fewer side effects. In this review, we highlight various strategies, namely computational biology ( in silico), in vitro enzymatic and cell assays, and in vivo animal tests, for seeking natural DPP-4 inhibitors from botanic sources including herbs and plants. The pros and cons of all approaches for new inhibitor candidates or hits will be under discussion.

show abstract

Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication)

Cited by 20 publications

References 96 publications

Fucose Ameliorates Tritrichomonas sp.-Associated Illness in Antibiotic-Treated Muc2−/− Mice

Fucose Ameliorates Tritrichomonas sp.-Associated Illness in Antibiotic-Treated Muc2−/− Mice

Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study

The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from in silico to in vivo

Contact Info

Product

Resources

About